Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Influenza

Free Subscription Articles published in Arch Virol Retrieve available abstracts of 141 articles: HTML format

Single Articles

April 2024
1. KUTKAT O, Gomaa M, Aboulhoda BE, Moatasim Y, et al
   Genetic and virological characteristics of a reassortant avian influenza A H6N1 virus isolated from wild birds at a live-bird market in Egypt.
   Arch Virol. 2024;169:95.
   PubMed     Abstract available
   
   
   
2. TRAN DH, Do HDK, Tran HT, Pham TNM, et al
   Rapid identification of SARS-CoV-2 strains via isothermal enzymatic recombinase amplification and nanopore sequencing.
   Arch Virol. 2024;169:87.
   PubMed     Abstract available
   
   
   March 2024
3. LI X, Ding G, Li S, Liu C, et al
   Proteomic characteristics of the treatment trajectory of patients with COVID-19.
   Arch Virol. 2024;169:84.
   PubMed     Abstract available
   
   
   
4. YUAN J, Pan J, Zhang X, Gao R, et al
   TRIM21 reduces H1N1-induced inflammation and apoptosis by regulating the TBK1-IRF3 signaling pathway in A549 cells.
   Arch Virol. 2024;169:74.
   PubMed     Abstract available
   
   
   February 2024
5. KIM HJ, Park JG, Moon KS, Jung SB, et al
   Identification and characterization of a marine bacterium extract from Mameliella sp. M20D2D8 with antiviral effects against influenza A and B viruses.
   Arch Virol. 2024;169:41.
   PubMed     Abstract available
   
   
   January 2024
6. ZHUANG J, Yan Z, Zhou T, Li Y, et al
   The role of receptors in the cross-species spread of coronaviruses infecting humans and pigs.
   Arch Virol. 2024;169:35.
   PubMed     Abstract available
   
   
   
7. WANG Y, Liu Y, Wang Y, Mai H, et al
   Clinical characteristics of outpatients with influenza-B-associated pneumonia and molecular evolution of influenza B virus in Beijing, China, during the 2021-2022 influenza season.
   Arch Virol. 2024;169:30.
   PubMed     Abstract available
   
   
   
8. TANIGUCHI K, Noshi T, Omoto S, Sato A, et al
   The impact of PA/I38 substitutions and PA polymorphisms on the susceptibility of zoonotic influenza A viruses to baloxavir.
   Arch Virol. 2024;169:29.
   PubMed     Abstract available
   
   
   
9. LIU H, Wang J, Li S, Sun Y, et al
   The unfolded protein response pathway as a possible link in the pathogenesis of COVID-19 and sepsis.
   Arch Virol. 2024;169:20.
   PubMed     Abstract available
   
   
   November 2023
10. JAMSHIDINIA N, Saadatpour F, Arefian E, Mohammadipanah F, et al
    Augmented antiviral activity of chlorhexidine gluconate on herpes simplex virus type 1, H1N1 influenza A virus, and adenovirus in combination with salicylic acid.
    Arch Virol. 2023;168:302.
    PubMed     Abstract available
    
    
    
11. ABDUL-KAREEM HH, Al-Maqtoofi MY, Burghal AA
    Impact of COVID-19 vaccination on saliva immune barriers: IgA, lysozyme, and lactoferrin.
    Arch Virol. 2023;168:293.
    PubMed     Abstract available
    
    
    
12. WAN L, Li L, Zhang H, Liu C, et al
    The changing pattern of common respiratory viruses among children from 2018 to 2021 in Wuhan, China.
    Arch Virol. 2023;168:291.
    PubMed     Abstract available
    
    
    October 2023
13. MOON SH, Na W, Shin S, Kim H, et al
    Evidence for the circulation of genotype 4 Eurasian avian-like lineage swine H1N1 influenza A viruses on Korean swine farms, obtained using a newly developed one-step multiplex RT-qPCR assay.
    Arch Virol. 2023;168:267.
    PubMed     Abstract available
    
    
    September 2023
14. MESEKO C, Ameji NO, Kumar B, Culhane M, et al
    Rational approach to vaccination against highly pathogenic avian influenza in Nigeria: a scientific perspective and global best practice.
    Arch Virol. 2023;168:263.
    PubMed     Abstract available
    
    
    
15. DAVE B, Shah KC, Chorawala MR, Shah N, et al
    Molnupiravir: an antiviral drug against COVID-19.
    Arch Virol. 2023;168:252.
    PubMed     Abstract available
    
    
    
16. DEGIUSEPPE JI, Martelli A, Barrios Mathieur C, Stupka JA, et al
    Genetic diversity of rotavirus A in Argentina during 2019-2022: detection of G6 strains and insights regarding its dissemination.
    Arch Virol. 2023;168:251.
    PubMed     Abstract available
    
    
    August 2023
17. TRIPATHY AS, Wagh P, Akolkar K, Walimbe AM, et al
    Association of inhibitory NKG2A and activating NKG2D natural killer cell receptor genes with resistance to SARS-CoV-2 infection in a western Indian population.
    Arch Virol. 2023;168:237.
    PubMed     Abstract available
    
    
    
18. PHAM NTK, Khamrin P, Shimizu-Onda Y, Hoque SA, et al
    Genetic diversity and declining norovirus prevalence in infants and children during Japan's COVID-19 pandemic: a three-year molecular surveillance.
    Arch Virol. 2023;168:231.
    PubMed     Abstract available
    
    
    
19. ZHOU Y, Chen Z
    Mpox: a review of laboratory detection techniques.
    Arch Virol. 2023;168:221.
    PubMed     Abstract available
    
    
    July 2023
20. MA H, Ren S, Meng Q, Su B, et al
    Role of Tim-3 in COVID-19: a potential biomarker and therapeutic target.
    Arch Virol. 2023;168:213.
    PubMed     Abstract available
    
    
    June 2023
21. FAYYAD-KAZAN M, Makki R, Homsi ME, Samadi A, et al
    Circulating microRNA profile in response to remdesivir treatment in coronavirus disease 2019 (COVID-19) patients.
    Arch Virol. 2023;168:194.
    PubMed     Abstract available
    
    
    
22. LOBAINA Y, Chen R, Suzarte E, Ai P, et al
    Broad humoral immunity generated in mice by a formulation composed of two antigens from the Delta variant of SARS-CoV-2.
    Arch Virol. 2023;168:190.
    PubMed     Abstract available
    
    
    
23. BHANOTHU V, Munne K, Pande S, Singh P, et al
    The dynamics of SARS-CoV-2 infection in unvaccinated and vaccinated populations in Mumbai, India, between 28 December 2020 and 30 August 2021.
    Arch Virol. 2023;168:188.
    PubMed     Abstract available
    
    
    
24. SENTHILAZHAGAN K, Sakthimani S, Kallanja D, Venkataraman S, et al
    SARS-CoV-2: analysis of the effects of mutations in non-structural proteins.
    Arch Virol. 2023;168:186.
    PubMed     Abstract available
    
    
    
25. UPADHYAY R, Tiwari KN
    The antiviral potential of Phyllanthus species: a systematic review.
    Arch Virol. 2023;168:177.
    PubMed     Abstract available
    
    
    
26. VALDES-LOPEZ JF, Urcuqui-Inchima S
    Antiviral response and immunopathogenesis of interleukin 27 in COVID-19.
    Arch Virol. 2023;168:178.
    PubMed     Abstract available
    
    
    
27. PATTANAIK A, Bhandarkar B S, Lodha L, Marate S, et al
    SARS-CoV-2 and the nervous system: current perspectives.
    Arch Virol. 2023;168:171.
    PubMed     Abstract available
    
    
    May 2023
28. ZHANG Y, Wang J, Xie Y, Cao X, et al
    Epidemiological characteristics of patients from fever clinics during the COVID-19 epidemic in 2022 in Shanghai, China.
    Arch Virol. 2023;168:164.
    PubMed     Abstract available
    
    
    
29. SUHARSONO H, Mahardika BK, Sudipa PH, Sari TK, et al
    Consensus insertion/deletions and amino acid variations of all coding and noncoding regions of the SARS-CoV-2 Omicron clades, including the XBB and BQ.1 lineages.
    Arch Virol. 2023;168:156.
    PubMed     Abstract available
    
    
    
30. TATSI EB, Koukou DM, Dellis C, Dourdouna MM, et al
    Epidemiological study of unusual rotavirus strains and molecular characterization of emerging P[14] strains isolated from children with acute gastroenteritis during a 15-year period.
    Arch Virol. 2023;168:149.
    PubMed     Abstract available
    
    
    April 2023
31. MANSOURABADI AH, Aghamajidi A, Dorfaki M, Keshavarz F, et al
    B lymphocytes in COVID-19: a tale of harmony and discordance.
    Arch Virol. 2023;168:148.
    PubMed     Abstract available
    
    
    
32. DA COSTA MA, de Almeida RPA, Ponde RAA
    Clinical-laboratory profile of children and adolescents with multisystem inflammatory syndrome temporarily associated with COVID-19 in Goias, Brazil.
    Arch Virol. 2023;168:142.
    PubMed     Abstract available
    
    
    
33. KAWABATA K, Sato Y, Kubo T, Tokumura A, et al
    Phospholipid analysis of two influenza A virus-infected cell lines differing in their viral replication kinetics.
    Arch Virol. 2023;168:132.
    PubMed     Abstract available
    
    
    March 2023
34. MARTINS M, do Nascimento GM, Conforti A, Noll JCG, et al
    A linear SARS-CoV-2 DNA vaccine candidate reduces virus shedding in ferrets.
    Arch Virol. 2023;168:124.
    PubMed     Abstract available
    
    
    
35. MAO L, Chen Y, Gu J, Zhao Y, et al
    Roles and mechanisms of exosomal microRNAs in viral infections.
    Arch Virol. 2023;168:121.
    PubMed     Abstract available
    
    
    
36. SHI T, Zhao X, Zhang X, Meng L, et al
    Immediate and long-term changes in the epidemiology, infection spectrum, and clinical characteristics of viral and bacterial respiratory infections in Western China after the COVID-19 outbreak: a modeling study.
    Arch Virol. 2023;168:120.
    PubMed     Abstract available
    
    
    
37. ZABIHI RIZI F, Ghorbani A, Zahtab P, Darbaghshahi NN, et al
    TYK2 single-nucleotide variants associated with the severity of COVID-19 disease.
    Arch Virol. 2023;168:119.
    PubMed     Abstract available
    
    
    
38. BORKAKOTI R, Karikalan M, Nehul SK, Jogi HR, et al
    A retrospective study showing a high rate of seropositivity against SARS-CoV-2 in wild felines in India.
    Arch Virol. 2023;168:109.
    PubMed     Abstract available
    
    
    February 2023
39. FALCON-CAMA V, Montero-Gonzalez T, Acosta-Medina EF, Guillen-Nieto G, et al
    Evidence of SARS-CoV-2 infection in postmortem lung, kidney, and liver samples, revealing cellular targets involved in COVID-19 pathogenesis.
    Arch Virol. 2023;168:96.
    PubMed     Abstract available
    
    
    
40. SALEM S, Mosaad R, Lotfy R, Elbadry M, et al
    Altered expression of DNA methyltransferases and methylation status of the TLR4 and TNF-alpha promoters in COVID-19.
    Arch Virol. 2023;168:95.
    PubMed     Abstract available
    
    
    
41. NEMOTO M, Reedy SE, Yano T, Suzuki K, et al
    Antigenic comparison of H3N8 equine influenza viruses belonging to Florida sublineage clade 1 between vaccine strains and North American strains isolated in 2021-2022.
    Arch Virol. 2023;168:94.
    PubMed     Abstract available
    
    
    
42. QUISPE-RICALDE MA, Castelan-Sanchez HG, Meza-Rodriguez PM, Davila-Ramos S, et al
    Evidence of natural selection and dominance of SARS-CoV-2 variant Lambda (C.37) over variants of concern in Cusco, Peru.
    Arch Virol. 2023;168:88.
    PubMed     Abstract available
    
    
    
43. RAMOS N, Panzera Y, Frabasile S, Tomas G, et al
    A multiplex-NGS approach to identifying respiratory RNA viruses during the COVID-19 pandemic.
    Arch Virol. 2023;168:87.
    PubMed     Abstract available
    
    
    
44. KAYED AE, Kutkat O, Kandeil A, Moatasim Y, et al
    Comparative pathogenic potential of avian influenza H7N3 viruses isolated from wild birds in Egypt and their sensitivity to commercial antiviral drugs.
    Arch Virol. 2023;168:82.
    PubMed     Abstract available
    
    
    January 2023
45. KHARROUBI G, Cherif I, Ghawar W, Dhaouadi N, et al
    Incidence and risk factors of SARS-CoV-2 infection among workers in a public health laboratory in Tunisia.
    Arch Virol. 2023;168:69.
    PubMed     Abstract available
    
    
    
46. PANAGIOTIDIS GD, Muller C, Binder M, Weber F, et al
    Influenza A virus strain PR/8/34, but neither HAM/2009 nor WSN/33, is transiently inhibited by the PB2-targeting drug paliperidone.
    Arch Virol. 2023;168:63.
    PubMed     Abstract available
    
    
    
47. FENG Z, Xu B, Zhong L, Chen J, et al
    A multicentre study on the incidence of respiratory viruses in children with community-acquired pneumonia requiring hospitalization in the setting of the zero-COVID policy in China.
    Arch Virol. 2023;168:64.
    PubMed     Abstract available
    
    
    
48. MITARAI S, Okuya K, Miyane K, Miyamoto M, et al
    Genetic characterization of bovine respiratory syncytial viruses in Japan between 2017 and 2019.
    Arch Virol. 2023;168:51.
    PubMed     Abstract available
    
    
    
49. REZAEE D, Bakhtiari S, Jalilian FA, Doosti-Irani A, et al
    Coinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza virus during the COVID-19 pandemic.
    Arch Virol. 2023;168:53.
    PubMed     Abstract available
    
    
    
50. PUENPA J, Rattanakomol P, Saengdao N, Chansaenroj J, et al
    Molecular characterisation and tracking of severe acute respiratory syndrome coronavirus 2 in Thailand, 2020-2022.
    Arch Virol. 2023;168:26.
    PubMed     Abstract available
    
    
    
51. VARELA APM, Sant'Anna FH, Dos Santos AV, Prichula J, et al
    Genomic evidence of SARS-CoV-2 reinfection cases in southern Brazil.
    Arch Virol. 2023;168:19.
    PubMed     Abstract available
    
    
    December 2022
52. NIU X, Xu J, Liu M, Tu H, et al
    Isolation and characterization of a SARS-CoV-2 variant with a Q677H mutation in the spike protein.
    Arch Virol. 2022;168:5.
    PubMed     Abstract available
    
    
    
53. FRAZZINI S, Amadori M, Turin L, Riva F, et al
    SARS CoV-2 infections in animals, two years into the pandemic.
    Arch Virol. 2022;167:2503-2517.
    PubMed     Abstract available
    
    
    
54. FU Y, Huang Y, Rao J, Zeng F, et al
    Host adaptation of codon usage in SARS-CoV-2 from mammals indicates potential natural selection and viral fitness.
    Arch Virol. 2022;167:2677-2688.
    PubMed     Abstract available
    
    
    November 2022
55. GRACHEVA AV, Korchevaya ER, Ammour YI, Smirnova DI, et al
    Immunogenic properties of SARS-CoV-2 inactivated by ultraviolet light.
    Arch Virol. 2022;167:2181-2191.
    PubMed     Abstract available
    
    
    
56. DE OLIVEIRA CM, Romano CM, Sussuchi L, Cota BDCV, et al
    SARS-CoV-2 BA.1 and BA.2 coinfection detected by genomic surveillance in Brazil, January 2022.
    Arch Virol. 2022;167:2271-2273.
    PubMed     Abstract available
    
    
    October 2022
57. DABAJA-YOUNIS H, Fuchs E, Shorbaji N, Appel T, et al
    SARS-CoV-2 and seasonal influenza: similarities and disparities.
    Arch Virol. 2022 Oct 21. pii: 10.1007/s00705-022-05615.
    PubMed     Abstract available
    
    
    
58. KARIMIAN A, Behjati M, Karimian M
    Molecular mechanisms involved in anosmia induced by SARS-CoV-2, with a focus on the transmembrane serine protease TMPRSS2.
    Arch Virol. 2022;167:1931-1946.
    PubMed     Abstract available
    
    
    
59. YELEMALI P, Hao L, Liu Q
    Mechanisms of host type I interferon response modulation by the nucleocapsid proteins of alpha- and betacoronaviruses.
    Arch Virol. 2022;167:1925-1930.
    PubMed     Abstract available
    
    
    September 2022
60. LI ZX, Feng S, Zhang H, Zhuang XY, et al
    Immunogenicity and protective efficacy of a DNA vaccine inducing optimal expression of the SARS-CoV-2 S gene in hACE2 mice.
    Arch Virol. 2022 Sep 9. pii: 10.1007/s00705-022-05562.
    PubMed     Abstract available
    
    
    August 2022
61. YANG F, Zhang X, Liu F, Yao H, et al
    Rapid emergence of a PB2 D701N substitution during adaptation of an H9N2 avian influenza virus in mice.
    Arch Virol. 2022 Aug 3. pii: 10.1007/s00705-022-05536.
    PubMed     Abstract available
    
    
    
62. NAGY A, Stara M, Vodicka R, Cernikova L, et al
    Reverse-zoonotic transmission of SARS-CoV-2 lineage alpha (B.1.1.7) to great apes and exotic felids in a zoo in the Czech Republic.
    Arch Virol. 2022;167:1681-1685.
    PubMed     Abstract available
    
    
    July 2022
63. NGWE TUN MM, Luvai E, Nwe KM, Toume K, et al
    Anti-SARS-CoV-2 activity of various PET-bottled Japanese green teas and tea compounds in vitro.
    Arch Virol. 2022;167:1547-1557.
    PubMed     Abstract available
    
    
    
64. BAHLAWAN O, Badra R, Semaan H, Fayad N, et al
    Prevalence and determinants of SARS-CoV-2 neutralizing antibodies in Lebanon.
    Arch Virol. 2022;167:1509-1519.
    PubMed     Abstract available
    
    
    June 2022
65. DAHER-NASHIF S, Al-Anany R, Ali M, Erradi K, et al
    COVID-19 exit strategy during vaccine implementation: a balance between social distancing and herd immunity.
    Arch Virol. 2022 Jun 20. pii: 10.1007/s00705-022-05495.
    PubMed     Abstract available
    
    
    May 2022
66. TAKIZAWA N, Momose F
    A novel E198K substitution in the PA gene of influenza A virus with reduced susceptibility to baloxavir acid.
    Arch Virol. 2022 May 5. pii: 10.1007/s00705-022-05456.
    PubMed     Abstract available
    
    
    
67. PIERI M, Nicolai E, Nuccetelli M, Sarubbi S, et al
    Validation of a quantitative lateral flow immunoassay (LFIA)-based point-of-care (POC) rapid test for SARS-CoV-2 neutralizing antibodies.
    Arch Virol. 2022;167:1285-1291.
    PubMed     Abstract available
    
    
    April 2022
68. NAGY A, Cernikova L, Stara M
    A new clade 2.3.4.4b H5N1 highly pathogenic avian influenza genotype detected in Europe in 2021.
    Arch Virol. 2022 Apr 26. pii: 10.1007/s00705-022-05442.
    PubMed     Abstract available
    
    
    
69. JIANG H, Yang T, Yang C, Lu Y, et al
    Molecular epidemiology and clinical characterization of human rhinoviruses circulating in Shanghai, 2012-2020.
    Arch Virol. 2022;167:1111-1123.
    PubMed     Abstract available
    
    
    
70. MWANGI P, Mogotsi M, Ogunbayo A, Mooko T, et al
    A decontamination strategy for resolving SARS-CoV-2 amplicon contamination in a next-generation sequencing laboratory.
    Arch Virol. 2022;167:1175-1179.
    PubMed     Abstract available
    
    
    
71. ALEJO-CANCHO I, Gual-de-Torrella A, Gallego M, Urrutikoetxea-Gutierrez M, et al
    Misidentification of the SARS-CoV-2 Mu variant using commercial mutation screening assays.
    Arch Virol. 2022;167:1141-1144.
    PubMed     Abstract available
    
    
    
72. ATIYA-NASAGI Y, Milrot E, Makdasi E, Schuster O, et al
    Development of an immunofluorescence assay for detection of SARS-CoV-2.
    Arch Virol. 2022;167:1041-1049.
    PubMed     Abstract available
    
    
    
73. COLSON P, Delerce J, Burel E, Dahan J, et al
    Emergence in southern France of a new SARS-CoV-2 variant harbouring both N501Y and E484K substitutions in the spike protein.
    Arch Virol. 2022;167:1185-1190.
    PubMed     Abstract available
    
    
    
74. WANG Y, Li P, Lavrijsen M, Li Y, et al
    Differing pan-coronavirus antiviral potency of boceprevir and GC376 in vitro despite discordant molecular docking predictions.
    Arch Virol. 2022;167:1125-1130.
    PubMed     Abstract available
    
    
    March 2022
75. DA SILVA MS, Mosena ACS, Baumbach L, Demoliner M, et al
    Cattle influenza D virus in Brazil is divergent from established lineages.
    Arch Virol. 2022 Mar 17. pii: 10.1007/s00705-022-05416.
    PubMed     Abstract available
    
    
    
76. BEHESHTIROUY S, Khani E, Khiali S, Entezari-Maleki T, et al
    Investigational antiviral drugs for the treatment of COVID-19 patients.
    Arch Virol. 2022;167:751-805.
    PubMed     Abstract available
    
    
    
77. LE TB, Kim HK, Ahn MJ, Zanin M, et al
    Diagnostic performance and clinical feasibility of a novel one-step RT-qPCR assay for simultaneous detection of multiple severe acute respiratory syndrome coronaviruses.
    Arch Virol. 2022;167:871-879.
    PubMed     Abstract available
    
    
    
78. KLOC M, Uosef A, Wosik J, Kubiak JZ, et al
    Virus interactions with the actin cytoskeleton-what we know and do not know about SARS-CoV-2.
    Arch Virol. 2022;167:737-749.
    PubMed     Abstract available
    
    
    February 2022
79. SALEHI-VAZIRI M, Fazlalipour M, Seyed Khorrami SM, Azadmanesh K, et al
    The ins and outs of SARS-CoV-2 variants of concern (VOCs).
    Arch Virol. 2022;167:327-344.
    PubMed     Abstract available
    
    
    
80. COLSON P, Fantini J, Yahi N, Delerce J, et al
    Limited spread of a rare spike E484K-harboring SARS-CoV-2 in Marseille, France.
    Arch Virol. 2022;167:583-589.
    PubMed     Abstract available
    
    
    
81. WANG HX, Zhang L, Liang ZT, Nie JH, et al
    Infectivity and antigenicity of pseudoviruses with high-frequency mutations of SARS-CoV-2 identified in Portugal.
    Arch Virol. 2022;167:459-470.
    PubMed     Abstract available
    
    
    
82. KIM Y, Jang G, Lee D, Kim N, et al
    Trypsin enhances SARS-CoV-2 infection by facilitating viral entry.
    Arch Virol. 2022;167:441-458.
    PubMed     Abstract available
    
    
    
83. ZHANG L, Guo X, Jiang H, Zhao N, et al
    Decreased incidence of acute hemorrhagic conjunctivitis associated with enhanced public health intervention during the COVID-19 epidemic in China, 2020.
    Arch Virol. 2022;167:577-581.
    PubMed     Abstract available
    
    
    
84. SHRIVASTAVA S, Mhaske ST, Modak MS, Virkar RG, et al
    Emergence of two distinct variants of SARS-CoV-2 and an explosive second wave of COVID-19: the experience of a tertiary care hospital in Pune, India.
    Arch Virol. 2022;167:393-403.
    PubMed     Abstract available
    
    
    
85. SAFARI I, Elahi E
    Evolution of the SARS-CoV-2 genome and emergence of variants of concern.
    Arch Virol. 2022;167:293-305.
    PubMed     Abstract available
    
    
    January 2022
86. FUMAGALLI MJ, Capato CF, de Castro-Jorge LA, de Souza WM, et al
    Stability of SARS-CoV-2 and other airborne viruses under different stress conditions.
    Arch Virol. 2022;167:183-187.
    PubMed     Abstract available
    
    
    December 2021
87. BUITRAGO SP, Garzon-Ospina D
    Genetic diversity of SARS-CoV-2 in South America: demographic history and structuration signals.
    Arch Virol. 2021;166:3357-3371.
    PubMed     Abstract available
    
    
    
88. TRIPATHY AS, Vishwakarma S, Trimbake D, Gurav YK, et al
    Pro-inflammatory CXCL-10, TNF-alpha, IL-1beta, and IL-6: biomarkers of SARS-CoV-2 infection.
    Arch Virol. 2021;166:3301-3310.
    PubMed     Abstract available
    
    
    
89. SHI B, Song Q, Luo X, Song J, et al
    Identification of cryptic putative IRESs within the ORF encoding the nonstructural proteins of the human rhinovirus 16 genome.
    Arch Virol. 2021;166:3373-3386.
    PubMed     Abstract available
    
    
    November 2021
90. VIJAYAKUMAR P, Raut AA, Chingtham S, Murugkar HV, et al
    Proteomic analysis of differential expression of lung proteins in response to highly pathogenic avian influenza virus infection in chickens.
    Arch Virol. 2021 Nov 16. pii: 10.1007/s00705-021-05287.
    PubMed     Abstract available
    
    
    
91. TSUNEKI-TOKUNAGA A, Kondo T, Kanai K, Itagaki A, et al
    Local spread of influenza A (H1N1) viruses without a mutation for the maximum duration of an epidemic season in Japan.
    Arch Virol. 2021 Nov 11. pii: 10.1007/s00705-021-05301.
    PubMed     Abstract available
    
    
    
92. WANG S, Liu Y, Yu L, Liang T, et al
    A strain of highly pathogenic porcine reproductive and respiratory syndrome virus: genomic characterization, pathogenicity, and construction of an infectious full-length cDNA clone.
    Arch Virol. 2021;166:3127-3141.
    PubMed     Abstract available
    
    
    
93. RASTEGAR M, Samadizadeh S, Yasaghi M, Moradi A, et al
    Functional variation (Q63R) in the cannabinoid CB2 receptor may affect the severity of COVID-19: a human study and molecular docking.
    Arch Virol. 2021;166:3117-3126.
    PubMed     Abstract available
    
    
    
94. DU X, Wu G, Zhu Y, Zhang S, et al
    Exploring the epidemiological changes of common respiratory viruses since the COVID-19 pandemic: a hospital study in Hangzhou, China.
    Arch Virol. 2021;166:3085-3092.
    PubMed     Abstract available
    
    
    
95. RODRIGUEZ-MALDONADO AP, Vazquez-Perez JA, Cedro-Tanda A, Taboada B, et al
    Emergence and spread of the potential variant of interest (VOI) B.1.1.519 of SARS-CoV-2 predominantly present in Mexico.
    Arch Virol. 2021;166:3173-3177.
    PubMed     Abstract available
    
    
    October 2021
96. JANG Y, Seo SH
    H5 cleavage-site peptide vaccine protects chickens from lethal infection by highly pathogenic H5 avian influenza viruses.
    Arch Virol. 2021 Oct 25. pii: 10.1007/s00705-021-05284.
    PubMed     Abstract available
    
    
    
97. DOMNICH A, De Pace V, Pennati BM, Caligiuri P, et al
    Evaluation of extraction-free RT-qPCR methods for SARS-CoV-2 diagnostics.
    Arch Virol. 2021;166:2825-2828.
    PubMed     Abstract available
    
    
    
98. HU J, Stojanovic J, Yasamineh S, Yasamineh P, et al
    The potential use of microRNAs as a therapeutic strategy for SARS-CoV-2 infection.
    Arch Virol. 2021;166:2649-2672.
    PubMed     Abstract available
    
    
    September 2021
99. SUN Y, Mao H, Lou X, Wang X, et al
    Molecular epidemiologic characteristics of hemagglutinin from five waves of avian influenza A (H7N9) virus infection, from 2013 to 2017, in Zhejiang Province, China.
    Arch Virol. 2021 Sep 30. pii: 10.1007/s00705-021-05233.
    PubMed     Abstract available
    
    
    
100. LAVERACK M, Tallmadge RL, Venugopalan R, Cronk B, et al
     Clinical evaluation of a multiplex real-time RT-PCR assay for detection of SARS-CoV-2 in individual and pooled upper respiratory tract samples.
     Arch Virol. 2021;166:2551-2561.
     PubMed     Abstract available
     
     
     
101. NAGY A, Basiouni S, Parvin R, Hafez HM, et al
     Evolutionary insights into the furin cleavage sites of SARS-CoV-2 variants from humans and animals.
     Arch Virol. 2021;166:2541-2549.
     PubMed     Abstract available
     
     
     
102. MARCHIO A, Batejat C, Vanhomwegen J, Feher M, et al
     ddPCR increases detection of SARS-CoV-2 RNA in patients with low viral loads.
     Arch Virol. 2021;166:2529-2540.
     PubMed     Abstract available
     
     
     
103. ABDELWAHAB SF, Mohamed MK, Ali WY, Ali AS, et al
     Role of polymeric materials in preventing COVID-19 infection.
     Arch Virol. 2021;166:2487-2493.
     PubMed     Abstract available
     
     
     
104. BOONARKART C, Suptawiwat O, Ruangrung K, Maneechotesuwan K, et al
     Microparticles from human the lower airway show inhibitory activity against respiratory syncytial virus.
     Arch Virol. 2021;166:2579-2584.
     PubMed     Abstract available
     
     
     
105. MA Y, Jiang H, Wan Z, Li S, et al
     Evolutionary dynamics of group A and B respiratory syncytial virus in China, 2009-2018.
     Arch Virol. 2021;166:2407-2418.
     PubMed     Abstract available
     
     
     August 2021
106. PENG J, Liu ZY, Yu XJ, Chen XY, et al
     Antibody response in COVID-19 patients with and without re-positive RT-PCR results during the convalescent phase.
     Arch Virol. 2021;166:2299-2303.
     PubMed     Abstract available
     
     
     
107. SHABBIR S, Raza MH, Arshad M, Khan MJ, et al
     The interplay between the immune system and SARS-CoV-2 in COVID-19 patients.
     Arch Virol. 2021;166:2109-2117.
     PubMed     Abstract available
     
     
     
108. HASHEMI SMA, Thijssen M, Hosseini SY, Tabarraei A, et al
     Human gene polymorphisms and their possible impact on the clinical outcome of SARS-CoV-2 infection.
     Arch Virol. 2021;166:2089-2108.
     PubMed     Abstract available
     
     
     
109. ZHANG L, Hou J, Ma FZ, Li J, et al
     The common risk factors for progression and mortality in COVID-19 patients: a meta-analysis.
     Arch Virol. 2021;166:2071-2087.
     PubMed     Abstract available
     
     
     July 2021
110. ZHOU S, Mao N, Zhang Y, Cui A, et al
     Genetic analysis of human parainfluenza virus type 4 associated with severe acute respiratory infection in children in Luohe City, Henan Province, China, during 2017-2018.
     Arch Virol. 2021 Jul 6. pii: 10.1007/s00705-021-05154.
     PubMed     Abstract available
     
     
     
111. YUAN HW, Wen HL
     Research progress on coronavirus S proteins and their receptors.
     Arch Virol. 2021;166:1811-1817.
     PubMed     Abstract available
     
     
     
112. MIRZAEI R, Attar A, Papizadeh S, Jeda AS, et al
     The emerging role of probiotics as a mitigation strategy against coronavirus disease 2019 (COVID-19).
     Arch Virol. 2021;166:1819-1840.
     PubMed     Abstract available
     
     
     June 2021
113. ZENG MS, Yu WD, Wang HX, Xu PP, et al
     Puerarin reduces impairment of intestinal and adipose immune responses to influenza virus infection in mice.
     Arch Virol. 2021 Jun 10. pii: 10.1007/s00705-021-05112.
     PubMed     Abstract available
     
     
     
114. CHEN K, Kong M, Liu J, Jiao J, et al
     Rapid differential detection of subtype H1 and H3 swine influenza viruses using a TaqMan-MGB-based duplex one-step real-time RT-PCR assay.
     Arch Virol. 2021 Jun 6. pii: 10.1007/s00705-021-05127.
     PubMed     Abstract available
     
     
     
115. ROKIC F, Trgovec-Greif L, Sucic N, Cemeljic N, et al
     Diverse SARS-CoV-2 variants preceded the initial COVID-19 outbreak in Croatia.
     Arch Virol. 2021;166:1735-1739.
     PubMed     Abstract available
     
     
     
116. PEDREANEZ A, Mosquera-Sulbaran J, Munoz N
     SARS-CoV-2 infection represents a high risk for the elderly: analysis of pathogenesis.
     Arch Virol. 2021;166:1565-1574.
     PubMed     Abstract available
     
     
     May 2021
117. TANG Y, Yang G, Li Y, Wang M, et al
     Protective effects of SP600125 on mice infected with H1N1 influenza A virus.
     Arch Virol. 2021 May 20. pii: 10.1007/s00705-021-05103.
     PubMed     Abstract available
     
     
     
118. SOKOLOVA AS, Yarovaya OI, Baranova DV, Galochkina AV, et al
     Quaternary ammonium salts based on (-)-borneol as effective inhibitors of influenza virus.
     Arch Virol. 2021 May 13. pii: 10.1007/s00705-021-05102.
     PubMed     Abstract available
     
     
     
119. SYLVERKEN AA, El-Duah P, Owusu M, Schneider J, et al
     Transmission of SARS-CoV-2 in northern Ghana: insights from whole-genome sequencing.
     Arch Virol. 2021;166:1385-1393.
     PubMed     Abstract available
     
     
     April 2021
120. GONZALEZ-GARCIA LD, Martinez-Castillo M, Vargas-Pavia TA, Ulloa-Aguilar JM, et al
     Inhibition of AMP-activated protein kinase in respiratory syncytial virus infection activates lipid metabolism.
     Arch Virol. 2021;166:1177-1182.
     PubMed     Abstract available
     
     
     March 2021
121. ZINYAKOV NG, Sosipatorova VY, Andriyasov AV, Ovchinnikova EV, et al
     Genetic analysis of genotype G57 H9N2 avian influenza virus isolate A/chicken/Tajikistan/2379/2018 recovered in Central Asia.
     Arch Virol. 2021 Mar 19. pii: 10.1007/s00705-021-05011.
     PubMed     Abstract available
     
     
     
122. WOUK J, Rechenchoski DZ, Rodrigues BCD, Ribelato EV, et al
     Viral infections and their relationship to neurological disorders.
     Arch Virol. 2021;166:733-753.
     PubMed     Abstract available
     
     
     
123. DOWLATSHAHI S, Shabani E, Abdekhodaie MJ
     Serological assays and host antibody detection in coronavirus-related disease diagnosis.
     Arch Virol. 2021;166:715-731.
     PubMed     Abstract available
     
     
     
124. DABBOUS HM, Abd-Elsalam S, El-Sayed MH, Sherief AF, et al
     Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study.
     Arch Virol. 2021;166:949-954.
     PubMed     Abstract available
     
     
     
125. VERMA J, Subbarao N
     A comparative study of human betacoronavirus spike proteins: structure, function and therapeutics.
     Arch Virol. 2021;166:697-714.
     PubMed     Abstract available
     
     
     
126. SARKAR R, Mitra S, Chandra P, Saha P, et al
     Comprehensive analysis of genomic diversity of SARS-CoV-2 in different geographic regions of India: an endeavour to classify Indian SARS-CoV-2 strains on the basis of co-existing mutations.
     Arch Virol. 2021;166:801-812.
     PubMed     Abstract available
     
     
     
127. HEMMAT N, Asadzadeh Z, Ahangar NK, Alemohammad H, et al
     The roles of signaling pathways in SARS-CoV-2 infection; lessons learned from SARS-CoV and MERS-CoV.
     Arch Virol. 2021;166:675-696.
     PubMed     Abstract available
     
     
     February 2021
128. YANG F, Xiao Y, Liu F, Yao H, et al
     Isolation and characterization of two novel reassortant H5N6 avian influenza viruses from waterfowl in eastern China.
     Arch Virol. 2021 Feb 17. pii: 10.1007/s00705-021-04995.
     PubMed     Abstract available
     
     
     
129. LI Y, Hu J, Lei J, Fan W, et al
     Development and application of a novel triplex protein microarray method for rapid detection of antibodies against avian influenza virus, Newcastle disease virus, and avian infectious bronchitis virus.
     Arch Virol. 2021 Feb 12. pii: 10.1007/s00705-021-04962.
     PubMed     Abstract available
     
     
     
130. TSUNEKI-TOKUNAGA A, Kanai K, Itagaki A, Tsuchie H, et al
     Growth capability of epidemic influenza viruses in Japan since the 2009 H1N1 pandemic.
     Arch Virol. 2021 Feb 12. pii: 10.1007/s00705-021-04976.
     PubMed     Abstract available
     
     
     January 2021
131. ALLKOFER A, Garvey M, Ryan E, Lyons R, et al
     Primary vaccination in foals: a comparison of the serological response to equine influenza and equine herpesvirus vaccines administered concurrently or 2 weeks apart.
     Arch Virol. 2021 Jan 7. pii: 10.1007/s00705-020-04846.
     PubMed     Abstract available
     
     
     
132. SABBAGHI A, Zargar M, Zolfaghari MR, Motamedi-Sedeh F, et al
     Protective cellular and mucosal immune responses following nasal administration of a whole gamma-irradiated influenza A (subtype H1N1) vaccine adjuvanted with interleukin-28B in a mouse model.
     Arch Virol. 2021 Jan 6. pii: 10.1007/s00705-020-04900.
     PubMed     Abstract available
     
     
     
133. NG KT, Takebe Y, Kamarulzaman A, Tee KK, et al
     Genome sequencing and phylogenetic reconstruction reveal a potential fourth rhinovirus species and its worldwide distribution.
     Arch Virol. 2021;166:225-229.
     PubMed     Abstract available
     
     
     
134. ARANCIO W
     ceRNA analysis of SARS-CoV-2.
     Arch Virol. 2021;166:271-274.
     PubMed     Abstract available
     
     
     
135. MOSQUERA-SULBARAN JA, Hernandez-Fonseca H
     Tetracycline and viruses: a possible treatment for COVID-19?
     Arch Virol. 2021;166:1-7.
     PubMed     Abstract available
     
     
     December 2020
136. REHMAN S, Mahmood T, Aziz E, Batool R, et al
     Identification of novel mutations in SARS-COV-2 isolates from Turkey.
     Arch Virol. 2020;165:2937-2944.
     PubMed     Abstract available
     
     
     November 2020
137. YANG X, Liang Y, Bamunuarachchi G, Xu Y, et al
     miR-29a is a negative regulator of influenza virus infection through targeting of the frizzled 5 receptor.
     Arch Virol. 2020 Nov 18. pii: 10.1007/s00705-020-04877.
     PubMed     Abstract available
     
     
     
138. LIU B, Wang Y, Liu Y, Chen Y, et al
     Molecular evolution and characterization of hemagglutinin and neuraminidase of influenza A(H1N1)pdm09 viruses isolated in Beijing, China, during the 2017-2018 and 2018-2019 influenza seasons.
     Arch Virol. 2020 Nov 3. pii: 10.1007/s00705-020-04869.
     PubMed     Abstract available
     
     
     
139. DADAR M, Fakhri Y, Bjorklund G, Shahali Y, et al
     The association between the incidence of COVID-19 and the distance from the virus epicenter in Iran.
     Arch Virol. 2020;165:2555-2560.
     PubMed     Abstract available
     
     
     
140. SHAMIM S, Khan M, Kharaba ZJ, Ijaz M, et al
     Potential strategies for combating COVID-19.
     Arch Virol. 2020;165:2419-2438.
     PubMed     Abstract available
     
     
     October 2020
141. GROHN S, Heinimaki S, Tamminen K, Blazevic V, et al
     Expression of influenza A virus-derived peptides on a rotavirus VP6-based delivery platform.
     Arch Virol. 2020 Oct 16. pii: 10.1007/s00705-020-04847.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Influenza is free of charge.